InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway
InflaRx計劃裁員，目標是將現金跑道延長至2027年中。
InflaRx N.V. (NASDAQ:IFRX) on thursday said it is taking decisive steps to cut costs, streamline operations, and extend its cash runway as it sharpens its focus on izicopan, its lead investigational asset, while significantly scaling back spending tied to Gohibic (vilobelimab).
InflaRx N.V.（納斯達克：IFRX）週四表示，正在採取果斷措施削減成本、精簡運營並延長其現金儲備，同時將重點放在其主要研究資產izicopan上，並大幅縮減與Gohibic（vilobelimab）相關的支出。
Gohibic is a medicine used to treat acute respiratory distress syndrome due to COVID-19 infection.
Gohibic是一種用於治療因COVID-19感染引起的急性呼吸窘迫綜合徵的藥物。
The company said the changes are intended to improve capital efficiency and support further development of izicopan across hidradenitis suppurativa (HS) and other inflammatory and immunology (I&I) indications.
公司表示，這些變化旨在提高資本效率，並支持izicopan在化膿性汗腺炎（HS）及其他炎症和免疫學（I&I）適應症中的進一步開發。
Restructuring Details
重組細節
As part of the restructuring, InflaRx is reducing its workforce...
作爲重組的一部分，I...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
